Mesothelioma

199P - Safety meta-analysis of clinical trials delivering TTFields to the upper torso

Authors
  • G. Ceresoli (Bergamo, Italy)
  • M. Pless (Winterthur, Switzerland)
Speakers
  • G. Ceresoli (Bergamo, Italy)

Previous ePoster
78P - Lung resection for cancer in patients with heart disease: Management and postoperative outcome

Next ePosters
79P - Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer
180TiP - An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer
No ePoster preview available
15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor
No ePoster preview available
80P - High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)
169P_PR - Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)
73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries
31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer
36P - Can a BALF profile distinguish hot vs cold lung tumors?
8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)
129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer